The project wants to shed a light at the late impacts of cancer in children; © panthermedia.net/
Is it possible to predict the likelihood of subsequent complications following cancer treatment on the basis of genetic tests? This is the main question to be addressed by an EU-wide research project that is being coordinated by the German Childhood Cancer Registry at the Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI) of the Mainz University Medical Center.
The project will focus on late effects of the childhood tumor therapy, such as fertility problems and hearing loss. In addition, the researchers aim to determine the overall effect of these complications on the health-related quality of life of former patients. The European Union will be providing funding of some EUR 6 million to support the research project entitled PanCareLIFE.
The prognosis for survival of patients who develop cancer as children has significantly improved in the last decades. Depending on the diagnosis, some 80 percent of those afflicted now experience remission. However, the improvement in the rate of long-term survival has also resulted in an increase of the rate of those likely to suffer late complications. These complications can take various forms, such as damage to organs (e.g., heart, kidneys, ear), impairment of the quality of life (due to growth problems, physical disabilities, intellectual impairment, or difficulty with social integration), and an increased risk of second cancer.
Researchers from eight European countries, i.e., the Czech Republic, Denmark, France, Germany, Ireland, Italy, the Netherlands, and Switzerland, will be participating in the PanCareLIFE project. The data from a total of about 12,000 former patients from all participating countries will be analyzed. The researchers involved hope to be able to use this data to identify genetic and non-genetic risk factors that may be associated with fertility problems and deafness. They thus intend to study genetic material in order to determine which genetic variants may be associated with the above-mentioned complications. The data collected during the PanCareLIFE project will be collated centrally at the German Childhood Cancer Registry of IMBEI at the Medical Center of Johannes Gutenberg University Mainz (JGU).
"It is a great honor for us that we here in Mainz at IMBEI have been assigned the coordination of this project and the responsibilities for collation of this valuable European data and the main statistical analysis," said Dr. Peter Kaatsch, Project Coordinator and Head of the German Childhood Cancer Registry. Professor Maria Blettner, Director of IMBEI, added: "The fact that we have improved the rate of long-term cancer survival is a great achievement. At the same time, this necessarily means that we need to focus on the possible late complications. PanCareLIFE can make a significant contribution here to the improvement of the long-term quality of life of survivors."
The German Childhood Cancer Registry has documented all cases of cancer occurring in children and adolescents in Germany since 1980. Some 50,000 cases have been recorded to date and more than 30,000 former patients are in long-term follow-up. The German Childhood Cancer Registry has been asked to act as coordinator for PanCareLIFE, a multinational research project initiated by the European Commission, due to its extensive experience with childhood cancer registration, familiarity with research into the causes and late complications of childhood cancer, and its international links with other institutions.
MEDICA.de; Source: Mainz University